Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Blood (2012) 120 (21): 1452.

https://doi.org/10.1182/blood.V120.21.1452.1452

Published: 2012

Journal Articles

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Blood (2010) 116 (21): 1066.

https://doi.org/10.1182/blood.V116.21.1066.1066

Published: 2010

Journal Articles

Validation of the European Leukemia Net (ELN) Genetic Classification of Acute Myeloid Leukemia: Inclusion of Monosomal Karyotype Improves Prognostic Discrimination

Blood (2010) 116 (21): 1712.

https://doi.org/10.1182/blood.V116.21.1712.1712

Published: 2010

Journal Articles

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Blood (2009) 114 (22): 4711.

https://doi.org/10.1182/blood.V114.22.4711.4711

Published: 2009

Journal Articles

Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype.

Blanca Espinet, PhD, Salaverría Itziar, PhD, Sílvia Beà, PhD, Neus Ruiz-Xivillé, Olga Balagué, MD, Marta Salido, Dolors Costa, PhD, Ana E Rodriguez, Juan LuíS. García, PhD, JesúS. M.ª Hernández-Rivas, MD, PhD, M.ª José Calasanz, PhD, Ana M Ferrer, MD, PhD, Antonio Salar, MD, PhD, Ana Carrió, PhD, Natividad Polo, Jose Antonio García-Marco, MD, PhD, Alicia Domingo, MD, Eva González-Barca, MD, PhD, Vicenç Romagosa, MD, Isabel Marugán, Armando López-Guillermo, MD, PhD, Fuensanta Millá, MD, José Luís Mate, MD, PhD, Elisa Luño, MD, PhD, Carmen Sanzo, MD, PhD, Rosa Collado, MD, PhD, Isabel Oliver, Sebastià Monzó, MD, Antonio Palacín, MD, Teresa González, Francesc Sant, MD, Ramon Salinas, MD, PhD, Mª Teresa Ardanaz, MD, Llorenç Font, MD, PhD, Lourdes Escoda, MD, Lourdes Florensa, MD, PhD, Elias Campo, MD, PhD, Sergi Serrano, MD, PhD, Francesc Solé, PhD

Blood (2008) 112 (11): 1765.

https://doi.org/10.1182/blood.V112.11.1765.1765

Published: 2008

Journal Articles

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

Blood (2005) 106 (12): 3755–3759.

https://doi.org/10.1182/blood-2005-03-1301

Published: 2005

NARROW

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Validation of the European Leukemia Net (ELN) Genetic Classification of Acute Myeloid Leukemia: Inclusion of Monosomal Karyotype Improves Prognostic Discrimination

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

Email alerts

ASH Publications

American Society of Hematology

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Validation of the European Leukemia Net (ELN) Genetic Classification of Acute Myeloid Leukemia: Inclusion of Monosomal Karyotype Improves Prognostic Discrimination

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only